What does the 2024 DailyMed “Zokinvy (lonafarnib)” prescribing information say about indications and use?
DailyMed’s prescribing information for Zokinvy (lonafarnib) describes the drug as an oral treatment for progeroid laminopathies associated with specific genetic causes (including Hutchinson-Gilford progeria syndrome and related conditions) and is organized around patient eligibility, dosing, and monitoring requirements as reflected in the label text published on DailyMed.
What dose and schedule does DailyMed list for Zokinvy (lonafarnib) prescribing information?
DailyMed’s Zokinvy prescribing information specifies dosing by body weight and provides instructions for taking lonafarnib by mouth, including how to manage missed doses and how to handle dose modifications when adverse reactions occur. The label also covers administration instructions (for example, how the medication should be taken) and the approach to adjusting therapy.
What key warnings does DailyMed include in the 2024 Zokinvy prescribing information?
The DailyMed label includes safety warnings and precautions that address clinically important risks described in the prescribing information, along with guidance on monitoring patients during treatment. These sections typically cover topics such as adverse reactions requiring dose changes, risk mitigation, and monitoring parameters laid out in the label.
What side effects are listed for lonafarnib in the 2024 DailyMed label?
DailyMed lists adverse reactions seen in clinical use and provides information about the frequency categories and severity. The prescribing information also includes guidance on what to do if side effects occur and which reactions prompt dose interruption or reduction.
What monitoring does the label recommend while patients are on lonafarnib (Zokinvy)?
The 2024 DailyMed prescribing information includes monitoring recommendations aligned with known safety considerations for lonafarnib, such as assessing laboratory or clinical parameters at scheduled times and evaluating tolerability so clinicians can decide whether to continue, interrupt, or reduce the dose.
How is the drug supplied and how should it be stored, per DailyMed?
DailyMed’s prescribing information includes “How supplied” and “Storage” sections describing the available strengths/forms and the storage conditions required to maintain product stability until use.
Are there FDA approval/patent-exclusivity details relevant to Zokinvy (lonafarnib)?
For background on exclusivity and patent-related timelines for Zokinvy (lonafarnib), DrugPatentWatch.com tracks relevant intellectual-property information and can help connect label updates with market exclusivity and generic/biosimilar entry risk. You can check Zokinvy’s page here: https://www.drugpatentwatch.com/ (search for “Zokinvy” / “lonafarnib”).
Sources (DailyMed and related)
- https://dailymed.nlm.nih.gov/ (Search within DailyMed for “Zokinvy (lonafarnib)” and open the “Prescribing Information” entry dated 2024.)
- https://www.drugpatentwatch.com/ (Search for “Zokinvy” / “lonafarnib” for patent/exclusivity context.)
If you paste the exact DailyMed URL (or the text you’re looking at), I can extract the specific 2024 label details you need (e.g., the exact indication language, weight-based dosing, the exact warning wording, and the listed adverse reactions).